U 106161

Drug Profile

U 106161

Alternative Names: PNU 106161

Latest Information Update: 19 Jun 2000

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Antipsychotics
  • Mechanism of Action Dopamine D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 19 Jun 2000 No-Development-Reported for Schizophrenia in USA (Unknown route)
  • 10 Jul 1997 New profile
  • 10 Jul 1997 Preclinical development for Schizophrenia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top